drugset
drugset / Trial / NCT01890109

Study of Erenumab (AMG 334) in Women With Hot Flashes

NCT01890109 ↗

Phase 1 Completed 103 enrolled Amgen
RandomizedParallel-groupTriple-blindPrevention

Summary

The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.

Timeline

Start
2013-05-13
Primary completion
2014-03-11
Completion
2014-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Erenumab Monoclonal antibody 70 mg Subcutaneous

Indications

No indication recorded.